Buprenorphine in Acute Renal Colic Pain Management
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01546701|
Recruitment Status : Completed
First Posted : March 7, 2012
Last Update Posted : December 10, 2012
|Condition or disease||Intervention/treatment||Phase|
|Acute Pain Management Renal Colic||Drug: Buprenorphine Drug: Morphine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Study Start Date :||March 2011|
|Actual Primary Completion Date :||April 2012|
|Actual Study Completion Date :||April 2012|
Renal Colic Patients treated by 2 mg sublingual Buprenorphine.
2 mg sublingual tablet
Active Comparator: Morphine
Renal Colic Patients treated by 0.1 mg/kg intravenous morphine.
0.1 mg/kg IV morphine
- change in pain score [ Time Frame: 20 and 40 minutes ]change in pain severity based on Numerical Rating Score
- treatment side effects [ Time Frame: 40 minutes ]experiencing any side effects by the patients as a result of treatment protocols.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01546701
|Iran, Islamic Republic of|
|Tehran, Iran, Islamic Republic of, 1417613151|
|Study Director:||Mohammad Jalili, MD||TUMS|